ClinicalTrials.gg
Active, not recruitingNCT06092476REMINDUpdated Aug 6, 2026

Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients

An interventional study of Revita® DMR Treatment and Sham procedure in Diabetes Mellitus, Type 2, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Planned enrollment
10th of 10
18 · median 36
Started
2024
the only one that year
No phase
9 of 12
1 open now
Registered
11th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

The objective of this study is to evaluate feasibility, safety, and efficacy of endoscopic DMR Treatment Paradigm 1 (compared to sham) and to evaluate feasibility, safety, and efficacy of re-treatment with DMR at 24 weeks (compared to baseline and a single DMR procedure) in patients with type 2 diabetes with non-insulin glucose lowering medications.

Read the detailed description

The objective of this study is to evaluate feasibility, safety, and efficacy of endoscopic DMR Treatment Paradigm 1 (compared to sham) and to evaluate feasibility, safety, and efficacy of re-treatment with DMR at 24 weeks (compared to baseline and a single DMR procedure) in patients with type 2 diabetes with non-insulin glucose lowering medications.

The aimed effect is an adequate or improved glucose regulation and a decrease of HbA1c. Secondary effects include improved cardiovascular, hepatic, and metabolic parameters.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 Diabetes
  • Duodenal ablation
  • Endoscopy
  • Duodenal Mucosal Resurfacing
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with Type 2 Diabetes.
  2. Age ≥ 18 to ≤ 75 years.
  3. Insulin naïve patients who are on stable dose (maximally approved or tolerated dose) of 2 or more glucose lowering drugs, including metformin, sulphonylurea (SU), (sodium-glucose cotransporter-2) inhibitors (SGLT-2i), Glucagon-like peptide-1 receptor agonists (GLP-1RA) or dipeptidyl peptidase 4 inhibitor (DPP-4i) and/or, thiazolidinedionderivaten (TZD) for at least 12 weeks.
  4. ≥ 24 and ≤ 40 kg/m2
  5. of ≥ 54 mmol/mol (7.5%) and ≤ 86 mmol/mol (10.0%).
  6. Signed and dated written in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled hyperglycemia with a glucose level >270 mg/dl (>15.0 mmol/L) after an overnight 8-hour fasting at the end of run-in and confirmed by a second measurement on the consecutive day.
  2. Subjects who are using insuline.
  3. Known case of absolute insulin deficiency as indicated by a fasting plasma C-peptide value of \<0.6 ng/ml (\<0,2 nmol/L).
  4. Diagnosis of diabetes/Type 1 diabetes mellitus, monogenic (neonatal or maturity onset diabetes of the young (MODY)) diabetes or Type 1 diabetes in adults/latent autoimmune diabetes of adults (LADA).
  5. History of more than 1 severe hypoglycemia episode or unawareness within past 6 months in which third party assistance was needed.
  6. valvular heart disease or severe aortic stenosis.
  7. Acute coronary syndrome (non-ST wave elevated myocardial infarction (STEMI), STEMI and unstable angina pectoris), stroke or within the past 3 months.
  8. Indication of acute liver disease, defined by serum levels of either (SGPT), AST (SGOT), or alkaline phosphatase above 3 x (ULN).
  9. Presence of acute or chronic active or C (except if is cured) or cirrhosis; or hepatic decompensation during the last 6 months; or alcoholic or autoimmune chronic hepatitis.
  10. Impaired renal function, defined as estimated (eGFR) \< 45 ml/min/1.73m2 or end stage renal failure or on dialysis.
  11. Diagnosed with esophageal motility disorder or Glomerular Filtration rate (GERD) gr 3 or diagnosed during screening endoscopy.
  12. Known history of a structural or functional disorder of the stomach, e.g. active gastric ulcer, chronic gastritis, gastric varices, hiatal hernia, stomach cancer or any other disorder of the stomach.
  13. Previous GI surgery that could affect the ability to treat the duodenum such as patients who have had a Billroth 2, Roux-and-Y gastric bypass, gastric sleeve or other similar procedures.
  14. Known intestinal autoimmune disease, including Celiac disease, or pre-existing symptoms of lupus erythematosus, scleroderma, or other autoimmune connective tissue disorder, which affects the small intestine.
  15. Patients with active helicobacter pylori infection. Patients may be enrolled if they had history of h-pylori infection and were successfully treated.
  16. History of active or partial remission from clinically significant malignancy within the past 5 years. With the exception of basal or squamous cell skin cancer or carcinoma in situ or those received curative treatment and in complete remission for 5 years or if subject confirmed as cancer free.
  17. Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cells (sickle cell trait is allowed).
  18. Known case of severe peripheral vascular disease.
  19. Clinically active systemic infection.
  20. Known status, including individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, clinically significant leukopenia or positive for the (HIV), on potential immunosuppressants.
  21. Current treatment with systemic or change in dosage of thyroid hormones within 6 weeks prior to consent or any other uncontrolled endocrine disorder.
  22. Use of anticoagulation therapy (such as warfarin, coumadin, Novel Oral AntiCoagulants (NOAC) or anti- agents (such as thienopyridine) which cannot be discontinued for 5-7 days or 2 drug half-lives before the procedure; Acetylsalicylic acid does not need to be discontinued.
  23. Actively participating in weight loss program or using medications for weight loss 3 months prior to randomization.
  24. General to deep or conscious sedation or general anesthesia or high risk (e.g., Classification (ASA) 4 or higher) or contraindications to upper GI Endoscopy.
  25. Nursing or Pregnant women or women of child bearing potential who are unwilling to practice acceptable method of .
  26. History of alcohol, legal or illegal drug and substance abuse.
  27. Intake of an drug in another trial within 30 days prior to consent or active participation in another clinical trial of an investigational drug or device.
  28. Any other clinical or mental condition which would jeopardize subject's safety or makes subject a poor candidate for clinical trial participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Active comparator
    DMR procedure

    Patients receive Revita® DMR Treatment Paradigm 1. After unblinding at 24 weeks, they receive retreatment.

    Device: Revita® DMR Treatment

  • Sham comparator
    Sham procedure

    Patients receive a sham procedure. After unblinding takes place at 24 weeks, patients receive a Revita® DMR Treatment Paradigm 1. 48 weeks after initial sham (= 24 weeks after first DMR) patients may receive retreatment, if they want to.

    Other: Sham procedure

Interventions

  • DeviceRevita® DMR Treatment

    The Revita® System is an endoscopic treatment consisting of a single catheter and console designed to lift the duodenal mucosa with saline followed by controlled circumferential hydrothermal ablation of the mucosa. For this study Revita® DMR procedure will be conducted as follows: DMR Treatment Paradigm 1- After initial 2 Lift and Ablate step, remaining Lift: Ablate steps will be conducted in 1:1 manner.

    Also known as: Revita® DMR Treatment Paradigm 1, Revita Duodenal Mucosal Resurfacing

  • OtherSham procedure

    The sham control for the Revita DMR procedure.

06

What researchers measure

Primary outcomes

  1. Safety endpoint

    Safety endpoint is evaluated 12 weeks post DMR and 12 weeks post retreatment with DMR \- Number (percentage) of patients experienced device and procedure-related Serious Adverse Events (SAEs), Unanticipated Device Effects (UADEs), Serious Adverse Device Effects (SADEs), Suspected Unexpected Serious Adverse Reaction (SUSARs)

    Time frame: 12 weeks post DMR and 12 weeks post retreatment with DMR

  2. Feasibility endpoint 1

    Feasibility endpoint is evaluated during and after the procedure: \- Number of ablations, whether a DMR was successful (\>3 ablations)

    Time frame: During procedure

  3. Feasibility endpoint 2

    Feasibility endpoint is evaluated during and after the procedure: \- Procedure time, defined as time between catheter in and catheter out.

    Time frame: During procedure

  4. Efficacy endpoint 1

    Efficacy is evaluated at 24 weeks compared to baseline and sham: \- Mean change in Fasting Plasma Glucose (FPG)/Flash Glucose Monitoring (FGM)

    Time frame: 24 weeks post DMR/sham

  5. Efficacy endpoint 2

    Efficacy is evaluated at 24 weeks compared to baseline and sham: \- Change in HbA1c

    Time frame: 24 weeks post DMR/sham

Secondary outcomes

  1. Secondary safety endpoint

    Secondary safety endpoint is evaluated during follow-up and compared to baseline and sham at week 24 and compared to baseline and 12 weeks after (re)-DMR for all patients: incidences and event rates of hypoglycemic events during complete study period

    Time frame: Through study completion, an average of 1 or 1,5 years

  2. Efficacy endpoint 1: mean change in HbA1c

    Efficacy endpoint 1: mean change in HbA1c

    Time frame: Through study completion, an average of 1 or 1,5 years

  3. Efficacy endpoint 2: mean Change in Fasting Glucose

    Efficacy endpoint 2: mean Change in Fasting Glucose

    Time frame: Through study completion, an average of 1 or 1,5 years

  4. Efficacy endpoint 2: mean Change in Time in Range (TIR)

    Efficacy endpoint 2: mean Change in Time in Range

    Time frame: Through study completion, an average of 1 or 1,5 years

  5. Efficacy endpoint 3: In patients with baseline abnormal Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) values, change in ALT, AST, GGT

    Efficacy endpoint 3: In patients with baseline abnormal ALT, AST and GGT values, change in ALT, AST, GGT

    Time frame: Through study completion, an average of 1 or 1,5 years

  6. Efficacy endpoint 4: Change in body weight

    Efficacy endpoint 4: Change in body weight

    Time frame: Through study completion, an average of 1 or 1,5 years

  7. Efficacy endpoint 5: Change in Fasting C-peptide

    Efficacy endpoint 5: Change in Fasting C-peptide

    Time frame: Through study completion, an average of 1 or 1,5 years

  8. Efficacy endpoint 6: Change in FPG

    Efficacy endpoint 6: Change in FPG

    Time frame: Through study completion, an average of 1 or 1,5 years

  9. Efficacy endpoint 7: Change in homeostasis model assessment for insulin resistance (HOMA-IR)

    Efficacy endpoint 7: Change in HOMA-IR

    Time frame: Through study completion, an average of 1 or 1,5 years

  10. Efficacy endpoint 8: Change in Framingham Risk Score-Cardiovascular risk score (FRS-CVD)

    Efficacy endpoint 8: Change in Framingham Risk Score-Cardiovascular risk score (FRS-CVD)

    Time frame: Through study completion, an average of 1 or 1,5 years

  11. Efficacy endpoint 9: Change in MRI-proton density fat fraction (MRI-PDFF)

    Efficacy endpoint 9: Change in MRI-PDFF

    Time frame: Through study completion, an average of 1 or 1,5 years

  12. Efficacy endpoint 10: Achievement of HbA1c ≤ 53 mmol/mol (7.0%)

    Efficacy endpoint 10: Achievement of HbA1c ≤ 53 mmol/mol (7.0%)

    Time frame: Through study completion, an average of 1 or 1,5 years

  13. Efficacy endpoint 11: Change in food intake (amount of calories, fat, carbohydrates, proteins etc.) based on intake registration data

    Efficacy endpoint 11: Change in food intake (amount of calories, fat, carbohydrates, proteins etc.) based on intake registration data

    Time frame: Through study completion, an average of 1 or 1,5 years

  14. Mechanistic: Change in resection tissue findings in morphological features

    Mechanistic: Change in morphological features

    Time frame: Week 12 after (re)DMR

  15. Mechanistic: Change in resection tissue findings in functional level changes

    Mechanistic: Change in functional level changes

    Time frame: Week 12 after (re)DMR

  16. Mechanistic: Change in resection tissue findings in cellular level changes

    Mechanistic: Change in cellular level changes

    Time frame: Week 12 after (re)DMR

  17. Mechanistic: Mean Changes in small intestinal biopsy gene expression

    Mechanistic: Mean Changes in small intestinal biopsy gene expression

    Time frame: Week 12 after (re)DMR

  18. Mechanistic: Mean Changes in small intestinal biopsy metabolomics/proteomics

    Mechanistic: Mean Changes in small intestinal biopsy metabolomics /proteomics

    Time frame: Week 12 after (re)DMR

  19. Mechanistic: Change in Plasma Citrulline

    Mechanistic: Change in Plasma Citrulline

    Time frame: Through study completion, an average of 1 or 1,5 years

  20. Mechanistic: Change in Cystatin Value

    Mechanistic: Change in Cystatin Value

    Time frame: Through study completion, an average of 1 or 1,5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 30 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 23, 2023
StartActual
Aug 9, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06092476
Collaborators
Fractyl Health Inc.
Responsible party
Jacques J.G.H.M. Bergman (Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 23, 2023
Start date
Aug 9, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

Jacques JG Bergman, MD, PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion